Tegal Corp (CLRX) 3.05 $CLRX
CollabRx to Present at Taglich Brothers 11th Annual Small Cap Equity Conference
GlobeNewswire - Tue Apr 29, 9:29AM CDT
via PRWEB - CollabRx, Inc. (Nasdaq CM: CLRX) is pleased to announce that Thomas Mika, Chairman, President & CEO will be presenting at Taglich Brothers 11th Annual Small Cap Equity Conference May 6, 2014. The Conference will take place at the New York Athletic Club, New York City. To get the detailed agenda, request additional information or register, contact Taglich Brothers at 212-779-2971 or visit http://www.TaglichBrothers.com. The entire event will be webcast and a link to the CollabRx presentation, which is sheduled to begin at 3:30 p.m. EDT on May 6, 2014, can be found on the company's website at http://www.collabrx.com.
CollabRx, Inc. To Present At Taglich Brothers 11th Annual Small Cap Equity Conference
PRWeb - Mon Apr 28, 3:11AM CDT
CollbRx, Inc. (Nasdaq CM: CLRX) is pleased to announce that Thomas Mika, Chairman, President & CEO will be presenting at Taglich Brothers 11th Annual Small Cap Equity Conference May 6, 2014. The Conference will take place at the New York Athletic Club, New York City. To get the detailed agenda, request additional information or register, contact Taglich Brothers at 212-779-2971 or visit http://www.TaglichBrothers.com.
CollabRx Partnership with Affymetrix Creates a Foundation
ACCESSWIRE - Tue Apr 22, 10:05AM CDT
WHITEFISH, MT / April 22, 2014 / Foundation Medicine Inc. (NYSE: FMI) made headlines in September 2013 with a well received $106 million IPO and a 78% first-day jump in share price. Despite lackluster demand for diagnostics stocks in general, investors jumped at the opportunity to invest in the company's unique approach of determining, in a single test of a cancer patient's tumor, whether any genetic mutations are present in literally hundreds of genes that can be paired with therapies that target those specific mutations.
CollabRx partners with Affymetrix to develop integrated clinical cancer panels
M2 - Thu Apr 17, 7:16AM CDT
CollabRx, Inc. (NASDAQ: CLRX) and Affymetrix, Inc. (NASDAQ: AFFX) said they have announced an agreement to optimize the use of CollabRx's Genetic Variant Annotation Service in connection with Affymetrix' OncoScan FFPE Assay Kit and CytoScan Cytogenetics Suite for analysis of gene copy number variation in cancer research.
CollabRx and Affymetrix Partner To Develop Analytical Tools For Integrated Clinical Cancer Panels
PRWeb - Wed Apr 16, 8:07AM CDT
CollabRx, Inc. (NASDAQ: CLRX), a leading provider of software and IT systems that support clinical decision-making in oncology, and Affymetrix, Inc. (NASDAQ: AFFX), an industry leader in genomics analysis, today announced an agreement to optimize the use of CollabRx's Genetic Variant Annotation (GVA) Service™ in connection with Affymetrix' OncoScan™ FFPE Assay Kit and CytoScan(R) Cytogenetics Suite for analysis of gene copy number variation (CNV) in cancer research.
CollabRx Appoints Paul Billings, MD, PhD to Board of Directors
GlobeNewswire - Tue Apr 08, 8:40AM CDT
via PRWEB - CollabRx, Inc. (Nasdaq:CLRX) today announced the appointment of Paul R. Billings, MD, PhD, FACP, FACMG to its Board of Directors. Dr. Billings is a nationally recognized expert on genomic and precision medicine.
CollabRx partners with Jackson Laboratory in molecular diagnostics for cancer
M2 - Thu Apr 03, 10:27AM CDT
CollabRx, Inc. (NASDAQ: CLRX) and The Jackson Laboratory said they have announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by JAX.
CollabRx and The Jackson Laboratory Partner in Molecular Diagnostics for Cancer
GlobeNewswire - Wed Apr 02, 8:43AM CDT
via PRWEB - CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on informing clinical decision-making in molecular medicine, and The Jackson Laboratory (JAX), an independent, nonprofit biomedical research institution with a staff of over 1,500 employees, today announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by JAX.
CollabRx: Making Sense of the Complex Cancer Market
ACCESSWIRE - Tue Apr 01, 9:02AM CDT
Cancer is one of the leading causes of death worldwide and the number of people affected by the disease is growing rapidly. In 2012, more than 14.1 million people around the world were newly diagnosed with some form of the disease. By 2035, the World Cancer Research Foundation expects these figures to increase to about 24 million new cases. These dynamics have attracted record numbers of researchers developing new therapeutics, diagnostics, and other tools designed to better treat patients.
Taglich Brothers Initiates Coverage on CollabRx Inc. (NASDAQ:CLRX) with Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Wed Mar 19, 10:09AM CDT
Vancouver, BC, March 19, 2014 - New York based investment firm Taglich Brothers has initiated coverage on CollabRx Inc. (NASDAQ:CLRX). Analyst Juan Noble gives the company a speculative buy rating, and a 12 month price target of $10.00, a premium of 188% to the $3.47 price on February 25th, the day the report was issued.
CollabRx Appoints Clifford Baron as Chief Operating Officer
GlobeNewswire - Wed Mar 05, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX) today announced the appointment of Clifford Baron, PhD as Vice President and Chief Operating Officer. Mr. Baron's most recent position was with Accelrys, Inc. a $160M+ global software provider serving pharmaceutical, biotechnology, chemical, and materials corporations.
Taglich Brothers Initiates Coverage on CollabRx, Inc.
Marketwire - Mon Mar 03, 9:01AM CST
Taglich Brothers, Inc. announces it initiated coverage of CollabRx, Inc.
10-Q: COLLABRX, INC.
Edgar Online - Thu Feb 13, 1:06PM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - (Amounts in thousands)
CollabRx Reports Third Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Tue Feb 11, 3:01PM CST
CollabRx, Inc. (the "Company"
(Nasdaq:CLRX) today announced financial results for the third quarter of fiscal year 2014, which ended December 31, 2013.
CollabRx, Inc. Schedules Third Quarter Fiscal Year 2014 Financial Conference Call and Business Update
GlobeNewswire - Fri Jan 31, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on genomics, today announced that it will hold an investor conference call on February 11, 2014 to discuss the Company's financial results for the third quarter of fiscal 2014 and to provide an update about the business in the current fiscal year.
CollabRx to Present at Taglich Brothers 11th Annual Small Cap Equity Conference
GlobeNewswire - Tue Apr 29, 9:29AM CDT
via PRWEB - CollabRx, Inc. (Nasdaq CM: CLRX) is pleased to announce that Thomas Mika, Chairman, President & CEO will be presenting at Taglich Brothers 11th Annual Small Cap Equity Conference May 6, 2014. The Conference will take place at the New York Athletic Club, New York City. To get the detailed agenda, request additional information or register, contact Taglich Brothers at 212-779-2971 or visit http://www.TaglichBrothers.com. The entire event will be webcast and a link to the CollabRx presentation, which is sheduled to begin at 3:30 p.m. EDT on May 6, 2014, can be found on the company's website at http://www.collabrx.com.
CollabRx, Inc. To Present At Taglich Brothers 11th Annual Small Cap Equity Conference
PRWeb - Mon Apr 28, 3:11AM CDT
CollbRx, Inc. (Nasdaq CM: CLRX) is pleased to announce that Thomas Mika, Chairman, President & CEO will be presenting at Taglich Brothers 11th Annual Small Cap Equity Conference May 6, 2014. The Conference will take place at the New York Athletic Club, New York City. To get the detailed agenda, request additional information or register, contact Taglich Brothers at 212-779-2971 or visit http://www.TaglichBrothers.com.
CollabRx Partnership with Affymetrix Creates a Foundation
ACCESSWIRE - Tue Apr 22, 10:05AM CDT
WHITEFISH, MT / April 22, 2014 / Foundation Medicine Inc. (NYSE: FMI) made headlines in September 2013 with a well received $106 million IPO and a 78% first-day jump in share price. Despite lackluster demand for diagnostics stocks in general, investors jumped at the opportunity to invest in the company's unique approach of determining, in a single test of a cancer patient's tumor, whether any genetic mutations are present in literally hundreds of genes that can be paired with therapies that target those specific mutations.
CollabRx partners with Affymetrix to develop integrated clinical cancer panels
M2 - Thu Apr 17, 7:16AM CDT
CollabRx, Inc. (NASDAQ: CLRX) and Affymetrix, Inc. (NASDAQ: AFFX) said they have announced an agreement to optimize the use of CollabRx's Genetic Variant Annotation Service in connection with Affymetrix' OncoScan FFPE Assay Kit and CytoScan Cytogenetics Suite for analysis of gene copy number variation in cancer research.
CollabRx and Affymetrix Partner To Develop Analytical Tools For Integrated Clinical Cancer Panels
PRWeb - Wed Apr 16, 8:07AM CDT
CollabRx, Inc. (NASDAQ: CLRX), a leading provider of software and IT systems that support clinical decision-making in oncology, and Affymetrix, Inc. (NASDAQ: AFFX), an industry leader in genomics analysis, today announced an agreement to optimize the use of CollabRx's Genetic Variant Annotation (GVA) Service™ in connection with Affymetrix' OncoScan™ FFPE Assay Kit and CytoScan(R) Cytogenetics Suite for analysis of gene copy number variation (CNV) in cancer research.
CollabRx Appoints Paul Billings, MD, PhD to Board of Directors
GlobeNewswire - Tue Apr 08, 8:40AM CDT
via PRWEB - CollabRx, Inc. (Nasdaq:CLRX) today announced the appointment of Paul R. Billings, MD, PhD, FACP, FACMG to its Board of Directors. Dr. Billings is a nationally recognized expert on genomic and precision medicine.
CollabRx partners with Jackson Laboratory in molecular diagnostics for cancer
M2 - Thu Apr 03, 10:27AM CDT
CollabRx, Inc. (NASDAQ: CLRX) and The Jackson Laboratory said they have announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by JAX.
CollabRx and The Jackson Laboratory Partner in Molecular Diagnostics for Cancer
GlobeNewswire - Wed Apr 02, 8:43AM CDT
via PRWEB - CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on informing clinical decision-making in molecular medicine, and The Jackson Laboratory (JAX), an independent, nonprofit biomedical research institution with a staff of over 1,500 employees, today announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by JAX.
CollabRx: Making Sense of the Complex Cancer Market
ACCESSWIRE - Tue Apr 01, 9:02AM CDT
Cancer is one of the leading causes of death worldwide and the number of people affected by the disease is growing rapidly. In 2012, more than 14.1 million people around the world were newly diagnosed with some form of the disease. By 2035, the World Cancer Research Foundation expects these figures to increase to about 24 million new cases. These dynamics have attracted record numbers of researchers developing new therapeutics, diagnostics, and other tools designed to better treat patients.
Taglich Brothers Initiates Coverage on CollabRx Inc. (NASDAQ:CLRX) with Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Wed Mar 19, 10:09AM CDT
Vancouver, BC, March 19, 2014 - New York based investment firm Taglich Brothers has initiated coverage on CollabRx Inc. (NASDAQ:CLRX). Analyst Juan Noble gives the company a speculative buy rating, and a 12 month price target of $10.00, a premium of 188% to the $3.47 price on February 25th, the day the report was issued.
CollabRx Appoints Clifford Baron as Chief Operating Officer
GlobeNewswire - Wed Mar 05, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX) today announced the appointment of Clifford Baron, PhD as Vice President and Chief Operating Officer. Mr. Baron's most recent position was with Accelrys, Inc. a $160M+ global software provider serving pharmaceutical, biotechnology, chemical, and materials corporations.
Taglich Brothers Initiates Coverage on CollabRx, Inc.
Marketwire - Mon Mar 03, 9:01AM CST
Taglich Brothers, Inc. announces it initiated coverage of CollabRx, Inc.
10-Q: COLLABRX, INC.
Edgar Online - Thu Feb 13, 1:06PM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - (Amounts in thousands)
CollabRx Reports Third Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Tue Feb 11, 3:01PM CST
CollabRx, Inc. (the "Company"
(Nasdaq:CLRX) today announced financial results for the third quarter of fiscal year 2014, which ended December 31, 2013. CollabRx, Inc. Schedules Third Quarter Fiscal Year 2014 Financial Conference Call and Business Update
GlobeNewswire - Fri Jan 31, 8:01AM CST
CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on genomics, today announced that it will hold an investor conference call on February 11, 2014 to discuss the Company's financial results for the third quarter of fiscal 2014 and to provide an update about the business in the current fiscal year.
